JP2013527173A5 - - Google Patents

Download PDF

Info

Publication number
JP2013527173A5
JP2013527173A5 JP2013509262A JP2013509262A JP2013527173A5 JP 2013527173 A5 JP2013527173 A5 JP 2013527173A5 JP 2013509262 A JP2013509262 A JP 2013509262A JP 2013509262 A JP2013509262 A JP 2013509262A JP 2013527173 A5 JP2013527173 A5 JP 2013527173A5
Authority
JP
Japan
Prior art keywords
methyl
pyridinyl
oxo
dihydro
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013509262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013527173A (ja
JP5889875B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/035344 external-priority patent/WO2012005805A1/en
Publication of JP2013527173A publication Critical patent/JP2013527173A/ja
Publication of JP2013527173A5 publication Critical patent/JP2013527173A5/ja
Application granted granted Critical
Publication of JP5889875B2 publication Critical patent/JP5889875B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013509262A 2010-05-07 2011-05-05 アザインダゾール Expired - Fee Related JP5889875B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33231410P 2010-05-07 2010-05-07
US61/332,314 2010-05-07
PCT/US2011/035344 WO2012005805A1 (en) 2010-05-07 2011-05-05 Azaindazoles

Publications (3)

Publication Number Publication Date
JP2013527173A JP2013527173A (ja) 2013-06-27
JP2013527173A5 true JP2013527173A5 (https=) 2014-06-26
JP5889875B2 JP5889875B2 (ja) 2016-03-22

Family

ID=45441481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013509262A Expired - Fee Related JP5889875B2 (ja) 2010-05-07 2011-05-05 アザインダゾール

Country Status (5)

Country Link
US (1) US8637509B2 (https=)
EP (1) EP2566479B1 (https=)
JP (1) JP5889875B2 (https=)
ES (1) ES2528269T3 (https=)
WO (1) WO2012005805A1 (https=)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
JP5864546B2 (ja) 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC インダゾール
EA023788B1 (ru) * 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
WO2011160206A1 (en) 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
AU2013203641B2 (en) * 2011-04-13 2014-08-21 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
EP2755962B1 (en) 2011-09-13 2017-03-01 Glaxosmithkline LLC Azaindazoles
CN104039956A (zh) 2011-11-04 2014-09-10 葛兰素史密斯克莱知识产权(第2号)有限公司 治疗方法
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドConstellation Pharmaceuticals,Inc. メチル基変更酵素の調節物質、組成物及びその使用
RU2704445C2 (ru) 2012-03-12 2019-10-28 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
AU2013237226A1 (en) 2012-03-19 2014-10-09 Emory University Quinazoline compounds and their use in therapy
US9394283B2 (en) * 2012-04-13 2016-07-19 Epizyme, Inc. Salt form of a human histone methyltransferase EZH2 inhibitor
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
US20150209367A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
CA2884848C (en) * 2012-09-28 2017-08-22 Pfizer Inc. Benzamide and heterobenzamide compounds
CA2887243C (en) 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
PE20150887A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
CA2894222A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
WO2014153214A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
US9765035B2 (en) 2013-03-14 2017-09-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153100A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
JP2016518336A (ja) 2013-03-14 2016-06-23 エピザイム,インコーポレイティド Prmt1阻害剤としてのピラゾール誘導体およびその使用
JP2016516046A (ja) 2013-03-14 2016-06-02 ジェネンテック, インコーポレイテッド がんの治療方法及びがん薬物耐性を阻止する方法
KR102028793B1 (ko) 2013-03-14 2019-10-07 에피자임, 인코포레이티드 아르기닌 메틸기 전이효소 억제제 및 이의 용도
EP2970137A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2014177982A1 (en) 2013-04-30 2014-11-06 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
AU2014288839B2 (en) 2013-07-10 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
EP3022195A2 (en) 2013-07-19 2016-05-25 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
KR102142177B1 (ko) 2013-10-16 2020-08-07 에피자임, 인코포레이티드 Ezh2 억제용 하이드로클로라이드 염 형태
US10603295B2 (en) 2014-04-28 2020-03-31 Massachusetts Eye And Ear Infirmary Sensorineural hair cell differentiation
CN105017221B (zh) * 2014-04-30 2019-05-28 中国医学科学院药物研究所 苯并咪唑衍生物及其制法和药物组合物与用途
TN2016000529A1 (en) 2014-06-17 2018-04-04 Pfizer Substituted dihydroisoquinolinone compounds
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
WO2016073956A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
US20190000860A1 (en) * 2014-11-06 2019-01-03 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
WO2016102493A1 (en) * 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
EP3236962A2 (en) 2014-12-23 2017-11-01 University of Copenhagen Treatment of cancer by inhibiting ezh2 activity
US10961532B2 (en) 2015-04-07 2021-03-30 The General Hospital Corporation Methods for reactivating genes on the inactive X chromosome
WO2017023671A1 (en) * 2015-08-03 2017-02-09 Constellation Pharmaceuticals, Inc. Ezh2 inhibitors and modulation of regulatory t-cell function
KR20180042356A (ko) 2015-08-24 2018-04-25 에피자임, 인코포레이티드 암 치료 방법
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
RS59763B1 (sr) * 2015-11-19 2020-02-28 Jiangsu Hengrui Medicine Co Derivati benzofurana, postupci njihove pripreme i njihova upotreba u medicini
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
EP3407901B1 (en) 2016-01-29 2021-07-21 Massachusetts Eye & Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
JP7174408B2 (ja) 2016-02-10 2022-11-17 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ 肝線維症のモデル系ならびにその作製および使用方法
JP7493304B2 (ja) 2016-04-22 2024-05-31 ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド Ezh2インヒビターおよびそれらの使用
WO2017192290A1 (en) 2016-05-04 2017-11-09 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and platinum-based antineoplastic drugs
CN109843870A (zh) 2016-10-19 2019-06-04 星座制药公司 Ezh2抑制剂的合成
EP3626715A4 (en) 2017-05-18 2021-03-24 Jiangsu Hengrui Medicine Co., Ltd. CRYSTAL OF A BENZOFURAND DERIVATIVE-FREE BASE AND MANUFACTURING PROCESS
BR112020008325A2 (pt) 2017-11-14 2020-10-20 Pfizer Inc. terapias de combinação com o inibidor de ezh2
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
AU2019373416A1 (en) 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
WO2020192652A1 (zh) 2019-03-25 2020-10-01 上海华汇拓医药科技有限公司 酰胺类化合物制备方法及其在医药领域的应用
WO2020216898A1 (en) 2019-04-24 2020-10-29 Institut Curie Biomarkers for predicting resistance to cancer drugs
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
MX2022001019A (es) 2019-07-31 2022-02-22 Ribon Therapeutics Inc Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
IL297327B2 (en) * 2020-05-01 2026-01-01 Gilead Sciences Inc 4,2-dioxopyrimidine compounds CD73 inhibitors
WO2022068929A1 (zh) * 2020-09-30 2022-04-07 武汉人福创新药物研发中心有限公司 嘧啶二酮类化合物及其用途
CN113292489B (zh) * 2021-06-16 2022-08-30 泓博智源(开原)药业有限公司 二氯代二烷基烟腈的制备方法
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ, インコーポレイテッド Cd73化合物
KR20250023481A (ko) 2022-06-13 2025-02-18 트리라인 바이오사이언시스, 인크. 1,8-나프티리딘-2-온 이종이작용성 bcl6 분해제
EP4536649A1 (en) 2022-06-13 2025-04-16 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2889526B1 (fr) * 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CA2651072A1 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2009006577A2 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
CA2722923C (en) * 2008-04-29 2016-08-02 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds

Similar Documents

Publication Publication Date Title
JP2013527173A5 (https=)
JP2013528591A5 (https=)
JP2013544840A5 (https=)
JP2013525498A5 (https=)
CA2798622A1 (en) Indoles
AU2006200437B2 (en) Substituted alkylamine derivatives and methods of use
AU2003252011B2 (en) Substituted 2-alkylamine nicotinic amide derivatives and use there of
KR101439823B1 (ko) 골수증식성 질환 및 기타 증식성 질환의 치료에 유용한 키나제 억제제
AU2016358242B2 (en) N-substituted indole derivatives as PGE2 receptor modulators
JP2018118992A5 (https=)
AU2018201953A1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
TW200413330A (en) Compounds for the treatment of abnormal cell growth
BR112020003254A2 (pt) moduladores da piruvato quinase e uso destes
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
HRP20180546T1 (hr) Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti
JP2014531465A5 (https=)
JP2015508828A5 (https=)
ME02416B (me) Trpv4 antagonisтi
JP2016500073A5 (https=)
AU2002248340A1 (en) Substituted alkylamine derivatives and methods of use
JP2020526556A5 (https=)
BRPI0721137A2 (pt) Compostos para modulação de atividade de c-fms e/ou c-kit e usos para os mesmos.
AU2007271964A1 (en) Pyrimidine derivatives as ALK-5 inhibitors
JP2015501784A5 (https=)
RU2009138137A (ru) Новые производные n-(8-гетероарилтетрагидронафталин-2-ил)-или n-(5-гетероарилхроман-3-ил)-карбоксамида для лечения боли